Bionomics Results Presentation Deck

PREVAIL Conclusions are Expected to Enable Late-Stage Development in SAD 22 SUDS Consistent trends in prespecified analyses • Significant effects observed in high anxiety phases of public speaking challenge • Increased confidence in SUDS for primary endpoint - EoPh2 discussion ● Subgroup Analyses Subgroup analyses of age groups and also delivered statistically significant results favoring BNC210 Dose Selection ● ● STAI-State ● BNC210 225 mg and 675 mg achieve similar separation from placebo Combination of active arms increases confidence in data ● Convergence of STAI-state analysis confirmed SUDS observations Potential for secondary endpoint in future late-stage SAD trials Bionomics

View entire presentation